Informação sobre produto
- Cgp 45715A
- (S-(R*,S*-(E,Z)))-7-((9-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-4H-1-benzopyran-2-carboxylic acid monosodium salt
- 1-Hydroxy-1-(3-trifluoromethylphenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid
- Cgp-45715 A
- 4H-1-Benzopyran-2-carboxylic acid, 7-((9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-, monosodium salt, (S-(R*,S*-(E,Z)))-
- sodium 7-{[(1S,2E,4Z)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-{(R)-hydroxy[3-(trifluoromethyl)phenyl]methyl}nona-2,4-dien-1-yl]sulfanyl}-4-oxo-4H-chromene-2-carboxylate
Iralukast Na is a leukotriene receptor antagonist that prevents bronchoconstrictor response. It binds to the cystic fibrosis transmembrane conductance regulator (CFTR) and blocks the binding of leukotrienes, which are potent bronchoconstrictors. Iralukast Na also blocks the activity of inflammatory cells and reduces bowel inflammation. Iralukast Na has been shown to be effective in treating asthma, inflammatory bowel disease, and other autoimmune diseases.
Propriedades químicas
Consulta técnica sobre: 3D-FS104155 Iralukast Na
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.